covid-19 symptoms infection patient

COVID-19 Scan for Jul 27, 2020

Reading now: 807
www.cidrap.umn.edu

Analysis of remdesivir COVID-19 trials posts encouraging resultsIn a comparative analysis published late last week in Clinical Infectious Diseases, the antiviral drug remdesivir was linked to significantly greater recovery and a 62% lower death rate by day 14 versus standard treatment in hospitalized adults with severe COVID-19.Researchers used data from 298 participants in an ongoing phase 3 trial of remdesivir at 45 international sites, as well as retrospective data from an ongoing real-world longitudinal study of 816 patients given standard treatment at 16 international sites.Patients in the remdesivir group were randomly assigned to receive standard treatment plus 200 milligrams (mg) of remdesivir on day 1, followed by either 4 or 8

Read more on cidrap.umn.edu
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA